invest.ei.ventures Open in urlscan Pro
2606:4700:3032::6815:57e3  Public Scan

Form analysis
1 forms found in the DOM

POST https://ei435.activehosted.com/proc.php

<form method="POST" action="https://ei435.activehosted.com/proc.php" id="_form_5_" class="_form _form_5 _inline-form _dark" novalidate="" data-v-484e2797=""><input type="hidden" name="u" value="5" data-v-484e2797="" data-name="u"><input type="hidden"
    name="f" value="5" data-v-484e2797="" data-name="f"><input type="hidden" name="s" data-v-484e2797="" data-name="s"><input type="hidden" name="c" value="0" data-v-484e2797="" data-name="c"><input type="hidden" name="m" value="0" data-v-484e2797=""
    data-name="m"><input type="hidden" name="act" value="sub" data-v-484e2797="" data-name="act"><input type="hidden" name="v" value="2" data-v-484e2797="" data-name="v">
  <div class="_form-content" data-v-484e2797="">
    <div class="_form_element _x99940696 _full_width _clear" data-v-484e2797="">
      <div class="_form-title popup-title" data-v-484e2797=""> Enter Your Email to Get Started </div>
    </div>
    <div class="_form_element _x27287557 _full_width" data-v-484e2797="">
      <div class="_field-wrapper" data-v-484e2797=""><input class="popup-input" type="text" id="email" name="email" placeholder="Email" required="" data-v-484e2797="" data-name="email"></div>
    </div>
    <div class="_button-wrapper _full_width" data-v-484e2797=""><button id="_form_5_submit" class="_submit popup-btn" type="submit" data-v-484e2797=""> Get Started </button></div>
    <div class="popup-privacy" data-v-484e2797="">We value your privacy and information</div>
    <div class="_clear-element" data-v-484e2797=""></div>
  </div>
  <div class="_form-thank-you" data-v-484e2797="" style="display: none;"></div>
</form>

Text Content

We're sorry but ei doesn't work properly without JavaScript enabled. Please
enable it to continue.
$19,914,863
RAISED
39.82%
COMPLETE
$498.94
MIN. INVESTMENT
$4.94
SHARE PRICE
Invest Now
view offering circular
 * The BIG Idea in 150 Words
 * 5 Reasons To Invest
 * Industry Data
 * The PSILLY Advantage
 * Offering Details

The BIG Idea in 150 Words
5 Reasons To Invest
Industry Data
The PSILLY Advantage
Offering Details
$19,914,863 / $49,999,999
RAISED
$34,937,553
REMAINING TO INVEST
$498.94
MIN. INVESTMENT
$4.94
SHARE PRICE
39.82%
COMPLETE
$19,914,863
RAISED
39.82%
COMPLETE
$498.94
MIN. INVESTMENT
$4.94
SHARE PRICE
A Major Paradigm Shift Is Underway... Which Could Be A Ray Of Hope For The
Millions Who Struggle With Mental Illness


"THE GOLDEN AGE OF PSYCHEDELICS"

If you've been looking to get in early... on what could potentially change
mental health and wellness... keep reading

Invest Now
Invest as little as $498.94

This Hawaii based company is poised to enter a combined $34.5 Billion market
with its Novel Botanical Psychedelic Drug pipeline and Mental Wellness Platform

How they intend to develop novel Botanical Psychedelic API... with the potential
for both therapeutic use and as the go-to company for Botanical Psilocybin
source material

And now, thanks to qualifying for a Reg A+ offering... everyday investors can
invest in the psychedelic future of mental health


THINKING TO INVEST IN THIS COMPANY?

Click The Button Below To Get Started
Invest Now


THE BIG IDEA IN 150 WORDS

Nearly a billion people worldwide struggle with mental illness. Of these, 284
million suffer from an anxiety disorder. It’s the unspoken crisis of our times.

The costs of this global crisis are enormous and yet... modern-day psychiatric
drugs are missing the mark. Big Pharma’s mental health solutions are outdated
and in many cases, they’re just not working.

Thankfully, a new paradigm is now emerging... which could dramatically shift the
way we treat mental health disorders... and its time has come.

The growing volume of scientific research is clear... Psychedelic medicine may
have the potential to reverse the epidemic of mental illness that is impacting
our world.

The Golden Age of Psychedelics Is Here.

And today... you have an opportunity to invest in a company planning to disrupt
the mental health space... with their exclusive Botanical Psilocybin API, their
whole plant Psychedelic Medicines and their online Wellness Platform.


MENTAL HEALTH... RE-IMAGINED

Never before in history have so many people been in such dire need of help and
support. That’s why Emotional Intelligence Ventures, also known as
Ei.Ventures... is fully committed to developing and deploying their psychedelic
solutions.

They aim to bring the healing power of these medicines to the world... and to
help usher in a new era of mental wellness around the globe.

Ei.Ventures believes that now is the time to re-imagine mental health... and
provide a platform for lasting change to occur. To this end... their holistic
approach and revenue model focuses on three distinct areas of potential revenue
growth.

If market response is any indication of where this industry could go... ATAI
Life Sciences(another company in the psychedelic space), recently went public on
Friday June 18th. They ended their first day of trading with a valuation of
nearly $3 billion dollars.

Momentum is building fast... and that’s a good thing... because the need of the
hour is great. Ei.Ventures is well-positioned to ride the wave of investor
interest... and intends to deliver psychedelic mental health solutions that make
a difference.

With a combined addressable market of $34.5 billionEi.Ventures intends to lead
from the front. We’ll talk more about their go-to-market strategy in just a
minute. Before we do, let’s take a quick look at when this paradigm shift
began... and where things go from here.


SEEKING THE MAGIC MUSHROOM

In May of 1957, Life Magazine published an article called, “Seeking The Magic
Mushroom.” It’s the story of two amateur mycologists who traveled to the remote
mountains of Mexico in search of Psilocybin Mushrooms.
This article changed the mental health landscape forever.
These two mushroom scientists became the first westerners to experience the
Mazatec sacred Psilocybin mushroom ritual... and the term “Magic Mushrooms”went
mainstream.
Soon after in 1958, Swiss chemist Albert Hofmann made one of the most important
molecular discoveries of the last century.
Hofmann was the first to identify the compounds Psilocybin and Psilocin... and
how they transform inside the human body.
Fast forward past the Psychedelic 60s... and past the war on drugs in the 70's
when psychedelics were made illegal... all the way to the year 2006. This is
when researchers at John Hopkins University published a landmark study on the
life-changing effects of a single dose of Psilocybin.
Just like that... a new industry was born.
Psilocybin and other psychedelic medicines were back on the map. Today, thanks
to new brain models and fMRI brain imaging technology... scientists believe
these molecules may be as close to a “Brain Reset” button as we could find.
What’s more... individuals struggling with anxiety, depression, PTSD, opioid use
disorder and other harmful addictions now have good reason to hope. The team at
Ei.Ventures looks at it this way...
Psilocybin and other psychedelics could be like the Rosetta Stone. They could
crack the code for healing a wide range of mental health disorders . This is the
promise of psychedelic medicine... and a potential megatrend in the making.


A HUGE PROBLEM HITS HOME

According to a recent report from the Lancet Commission... the global economic
costs of this mental health crisis could reach $16 trillion by 2030. In
addition, an estimated 12 billion working days will be lost each year as a
result.
While the financial impact of this crisis is mind-boggling on its own... the
personal costs can take a toll beyond what any human should ever have to deal
with.
Close relationships break down. Family life gets disrupted. People struggling
with conditions like anxiety, depression and PTSD may avoid interpersonal
contact... and could have a hard time maintaining their social networks.
Sarah N. shared her story at the website PsychAlive... and it’s heart-breaking:
“Mental illness feels like a crushing stone on my chest making it hard to
breathe. It makes me hopeless, alone, scared of myself, scared of everyone else,
helpless, embarrassed and ashamed.”
Our hearts go out to Sarah and all the brave spirits who are dealing with mental
health challenges. This is the silent epidemic we need to do something about.
And yes... there’s a financial cost at the personal level as well. A report
published in the journal Health Affairs estimates that for those with a serious
mental illness... the lifetime burden is a shocking $1.85 million. Mental
illness can dramatically decrease the quality of life as well. On average,
adults with mental illness will die 25 years earlier than those without these
conditions.
As bleak as this crisis may be... times like these also represent an opportunity
for innovation and new approaches... and that’s where Ei.Ventures, comes in.
Their flagship Botanical Psilocybin-based formulation is called “Psilly”. They
believe it could be a potential game-changer for people like Sarah N... and the
millions who struggle with mental illness every single day. More on Psilly in a
moment.


MODERN-DAY PSYCHIATRIC DRUGS ARE MISSING THE MARK

Big Pharma needs to fess up. When the psychiatric drug Prozac first came to
market in 1988, it was hailed as a mental health savior. In the meantime... 33
years later, depression affects more people than ever before. What gives?
It’s worth noting that Prozac was an instant cash cow for Eli Lily, the company
which developed the drug. Within three years, Prozac was flying out of doctor
offices... and became their biggest selling antidepressant of all time.
Not a good look for the pharmaceutical industry. It could make you wonder what
their motivation is.
Then there’s the possible side effects... which read like something from a low
budget horror movie. Here’s a partial list for Prozac:
Nausea, anxiety, insomnia, dizziness, weight changes, heart palpitations, sore
throat, dry mouth, decreased sex drive, impotence and difficulty having an
orgasm.
It’s no surprise that a majority of people don’t stay on their antidepressants.
Studies show between 56% - 87.6% of patients stop taking their medication.
What’s more, up to 30% of adults with Major Depressive Disorder (MDD) are
“treatment-resistant.”
The alarm bells have also been ringing for drugs used to treat PTSD. In a recent
study published in the Journal of Clinical Psychopharmacology... researchers
found that the drug prazosin may not reduce suicidal thoughts in PTSD patients.
And in another study published in the journal Chronic Stress... researchers
found that two thirds of U.S. veterans being treated for PTSD did not benefit
from their therapy.
It's growing clearer that a new approach is needed.... and nature’s psychedelic
plant medicines are answering the call.
It's growing clearer that a new approach is needed.... and nature’s psychedelic
plant medicines are answering the call.
They’ve been revered for thousands of years in cultures all around the globe.
Finally... 21st science is catching up with the ancient wisdom found within
these plants.


THE PSYCHEDELIC FUTURE IS CALLING

Today... there are millions with MDD and other mental health disorders who are
not getting well using traditional psychiatric drugs. This is potentially a huge
target market.
These folks deserve better... and Ei.Ventures intends to help bring the healing
power of psychedelic medicines to those who need it most. The company has plans
to ramp up the R&D pipeline for Psilly and its entire suite of Botanical
Psychedelic API.
To this end, a newly-formed partnership with Tioga Labs has been inked... which
will focus on creating unique delivery mechanisms for Psilly.
A number of novel applications are being considered which could potentially be
licensed as well.
Ei.Ventures is the only Psychedelic medicine company we are aware of to qualify
for a Reg A+ Tier 2 offering.
Today, both accredited and non-accredited investors have the opportunity to
purchase shares in Ei.Ventures.
The founders of Ei.Ventures believe in building a grass roots community of
investors who share their passion for this space.
THIS COULD BE YOUR OPPORTUNITY TO INVEST
IN THE FUTURE OF MENTAL HEALTH

Click The Button Below To Get Started
Invest Now


FIVE BIG REASONS TO CONSIDER INVESTING IN EI.VENTURES

Reason #1:
Their Flagship Product Psilly Could Potentially Be A GAME-CHANGER
Their flagship product Psilly is a whole-plant Botanical Psilocybin-based
formulation, which is currently in the pre-clinical phase. The goal is to get
through pre-clinical and phase 1 trials first... and then launch, if
appropriate, therapeutic Psilly into legal jurisdictions.
Psilly is a whole plant and fungi Botanical formulation. One of the reasons they
are developing Botanical formulations has to do with the Entourage Effect.
*Final packaging concept may change.
As you’ll read below... researchers have discovered a number other active
compounds within the Psilocybin mushroom. It’s this synergy among the compounds
that may play a role in the therapeutic effects.
Reason #2:
Their Science Team Has 30+ Years Experience In Bringing New Drugs To The Market
Their science and clinical team has 30+ years in bringing new drugs to the
market. Their knowledge and experience gives Ei.Ventures a competitive edge.
What’s more, they understand how to navigate the FDA approval process... which
is both capital and human resource intensive. This in itself creates a high
barrier to entry.
The first step in developing Psilly, their flagship therapeutic and drug
candidate, is to grow their own proprietary spores.
From here, the initial CMC studies (“Characterization, Manufacturing and
Controls”) will be done.
This allows them to create new Botanical API for their own studies and internal
R&D. This also allows them to potentially license their API through a Drug
Master File.
With all their formulations... Ei.Ventures has a continuing psychedelic drug
development plan to go down the FDA pathway through phase 2, phase 3, and FDA
approval.
Reason #3:
Botanical Psychedelic API And Drug Formulations
Ei.Ventures uses the whole plant and fungi in their Botanical formulations...
which has the potential to create something called the “Entourage Effect”.
Researchers suggest the Entourage Effect could be key to Psilocybin’s healing
properties.
There potentially could be greater benefits and results from this approach... as
compared to creating a single molecule synthetic Psilocybin drug in the lab.
This is what virtually all other companies in the space are doing. It’s also a
philosophical thing.
The founders at Ei.Ventures are inspired by Hawaiian traditions... among them
having reverence for the land and the medicinal plants which grow on it.
Honoring the wisdom found in nature is part of the Ei.Ventures creed. They are
fully committed to developing their Botanical Psychedelic API. Their vision is
fueled by a belief in the inherent healing power of the whole plant. The
research is beginning to suggest this to be true.
Reason #4:
Their Holistic Approach Creates Multiple Spokes Of Potential Revenue Psychedelic
API And Drug Formulations
The company has a holistic approach to mental health. Their platform combines
the use of Psychedelic Medicines, breakthrough science, the healing power of
plants and cutting-edge technology. This is their secret sauce.
They are targeting the medical and therapeutic markets with their psychedelic
solutions. As more states and cities legalize Psilocybin for therapeutic use...
the need for Psilly and their Botanical Psychedelic formulations is projected to
grow.
They are also targeting the consumer markets with their line of non-psychoactive
mushroom nutraceuticals, MANA.
The first to be launched in 2021 is Brain MANA... which is formulated to support
brain health, mental clarity and overall well-being.
The medicinal mushroom market is a $13 billion market... with an expected growth
rate of 9.4% CAGR through 2026. Revenues from their MANA line will help reduce
overall cash burn until FDA approval or an investment exit.
Finally, they also have plans to launch a Telepsychiatry App in 2021 as an
integral part of their Mental wellness Platform as well. The demand for
Telepsychiatry services is $5.5 billion dollar market with untapped potential...
and it’s growing fast. It is expected to grow at a compound annual growth rate
(CAGR) of 24.7% from 2020 to 2027.
Reason #5:
The Potential To Help Millions Of People Who Struggle With Mental Illness
You have the potential to help millions of people who struggle with mental
illness... whether it’s anxiety, depression, PTSD or an addiction to alcohol or
nicotine. There are many who aren’t finding the help they need with Big Pharma
drugs.
Many of these traditional drugs are outdated and ineffective. Their side effects
are potentially dangerous.
Those dealing with mental illness deserve better.
Ei.Ventures is fully committed to developing their library of Botanical
Psychedelic API, including Psilly... which is their answer to the Mental Health
crisis.
Your investment in Ei.Ventures today could potentially help many overcome the
impact mental illness is having on their lives. The company's founders believe
that as one individual gets well, there is a positive ripple effect that
benefits all.


THINKING TO INVEST IN THIS COMPANY?

Click The Button Below To Get Started
Invest Now


THE NEXT GENERATION OF PSYCHEDELIC MEDICINE IS BOTANICAL

Researchers recently discovered that magic mushrooms contain several key
compounds other than Psilocybin and Psilocin. What’s more, they suggest it’s the
sum total of these different parts which contribute to the healing properties
these mushrooms possess.
Their findings were published in the journal Chemistry Europe, in November 2019.
The new compounds they identified belong to a family of chemicals known as
“beta-carbolines.”
From a science perspective... beta‐carboline is also known as a MAOI, which
stands for “monoamine oxidase inhibitor”.
This is important... because the monoamine oxidase enzyme (MAO) breaks Psilocin
down in the body.
Researchers believe that the beta-carboline sustains the psychedelic experience
by preventing the Psilocin from breaking down. Hence, it is an “inhibitor”.
They go on to suggest that there is something called an “Entourage Effect” in
magic mushrooms... which may be the key to their healing properties.
In essence, the Entourage Effect is a synergistic interaction between two or
more different molecules found within the same plant. The same effect has been
found with Cannabis.
THC, CBD and the other dozens of other compounds within the Cannabis plant are
key to the overall experience. Various strains will have different effects on
the end-user.
The same effect is now believed to hold true with Psilocybin mushrooms. It’s
also why Ei.Ventures is developing Botanical (all fungi and plant based)
Psychedelic API and Therapeutics... instead of single molecule synthetic drugs.
They believe the research will continue to confirm the importance of a
synergistic approach. This sets them apart from virtually every other company in
the space... who are developing synthetic versions of Psilocybin in their labs.
In the end... Ei.Ventures believes the race to develop safe and effective
psychedelic medicines will be won in partnership with nature... not in the
confines of a scientific lab alone.


THE MENTAL HEALTH PARADIGM IS SHIFTING TO PSYCHEDELIC MEDICINE

The Psychedelic Medicine space has been heating up over the last several
years... and yet this emerging industry has been decades in the making.
Some investors have wondered whether its growth will mirror how the medical
marijuana industry evolved... and how cannabis stocks took off between 2014 and
2018. One question is whether this is a chance to get in early on what could be
the next potential plant medicine boon.
Keep in mind... recreational Psilocybin isn’t going to be available to the
general public at any time soon... if ever at all. Psilocybin and Psychedelic
medicine is being researched for its potential use in a legal, therapeutic
setting only.
That said... it’s possible the psychedelic industry could follow a similar path
as medical cannabis did towards legalization and therapeutic use. If so, the
financial growth curve could end up looking the same.
Several recent IPOs show that the industry is picking up a head of steam... and
attracting big-time investment capital as well. More on this in a moment.
If you’re considering whether this is a good time to invest in the psychedelic
medicine space... there are 4 key data points which suggest a Mental Health
paradigm shift is well underway.


INDUSTRY DATA SUGGESTS A POTENTIAL GROWTH TREND IS IN THE MAKING

Data point #1:
Psychedelic Research
We’ve come a long way since Life Magazine put “Magic Mushrooms” on the map in
1957. Since then... the amount of research published in leading medical and
scientific journals has more than quadrupled in the last 5-10 years.
Today... there’s no denying that Psilocybin and other Psychedelic medicines have
been shown to help improve mental health. Researchers are also finding that a
single dose of Psilocybin can enhance creative thinking, empathy, and well-being
in healthy adults.
In a new study published this July in the journal Neuron... researchers from
Yale University made another major discovery.
They found that a single dose of psilocybin given to mice prompted an immediate
and long-lasting increase in connections between neurons.
Not only did they see a 10% increase in the number of these neuron
connections... they were on average 10% stronger as well.
This mirrors what the company’s Director of Clinical Development, Linda Strause,
Ph.D, noted in an interview with SELF magazine. According to Dr. Strause...
“Psychedelics can stimulate the growth of new neurons as well as new connections
between them, which suggests they can help treat depression, PTSD, and other
issues.”
Ei.Ventures plans to ramp up their R&D with the monies raised from their Reg A+
Tier 2 offering. They are the first Psychedelic Medicine company in the world to
company to qualify for this type of “Mini-IPO” as it’s known.
The Botanical Psychedelic API pipeline includes formulations to be developed for
several mental health indications... including Major Depressive Disorder and
Anxiety Disorders.
Data point #2:
Psychedelic Patents
Patent filings can be a good indicator of what’s happening inside an industry.
With the growing volume of research fueling a paradigm shift in mental health...
more psychedelic patents are being filed than ever before.
This includes a large number of provisional patents, which protect the company’s
IP for 12 months while further research takes place. In 2020, there were 21
provisional patents filed... and through June 2021, there have been 12
provisional patents filed.
Ei.Ventures is building its own library of Botanical Psychedelic API... and
pursuing patent protection for a number of promising formulations.
The goal is to become the leading source of their exclusive Psilocybin
formulation to the industry.
Among their dossier of patents... the company holds the IP for the extraction
process of three botanical potential API compounds. Psilocybin, DMT and MDMA.
The plan is to further develop this API and then file a Drug Master File with
the FDA. This allows them to potentially sell the API to other organizations
while protecting their IP.
Their science and clinical team understands how to navigate the FDA approval
process. With all their formulations... Ei.Ventures has a continuing psychedelic
drug development plan to go down the FDA pathway through phase 2, phase 3, and
FDA approval.
Data point #3:
Psychedelic Clinical Trials
The number of clinical trials involving Psilocybin and other psychedelic
medicines is on the rise as well. This number has doubled in the last 3-5 years.
There are currently 43 different clinical trials in various stages of progress.
Researchers are further exploring how psychedelic medicine can potentially help
patients with depression, PTSD, anxiety, alcohol addiction and opioid use
disorder.
This includes over two dozen Phase I and Phase II clinical trials. One of these
is a major study on the effects of psilocybin used for treatment-resistant
depression.
Another will study the therapeutic potential of Psilocybin to treat chronic
Phantom Limb pain. This is a type of neuropathy which can cause a feeling of
extreme pain from a body part that is no longer there.
Researchers will also be seeking to better understand how Psilocybin may alter
brain circuitry. This is just one of several promising clinical trials underway.
Timothy Furnish, MD, from the UC San Diego School of Medicine is one of the lead
researchers on the team. What he said may get you even more excited about the
psychedelic medicine industry.
“Psilocybin has the potential to ‘reset’ altered cortical brain circuits
associated with certain chronic pain conditions. This reset could result in a
drug that works on an extended basis (days or weeks) or perhaps even constitutes
a ‘cure.’ We have already seen evidence that psilocybin may reset these
circuits.”
The momentum is building fast towards a Psychedelic Medicine future... and the
team at Ei.Ventures is ready to execute on its Psilly-inspired vision.
Data point #4:
Psychedelic Investment
Psilocybin and other psychedelic plant medicines have shown enormous potential
to help alleviate mental illness. Most agree there is an urgent need for safer
and more effective treatment options... and big money is flowing into the space
to develop these solutions.
Billionaire investors and a number of big hedge funds are getting involved. They
see the need for a new treatment approach... and they sense the opportunity.
One well-known billionaire investor who is betting big on psychedelics is Kevin
O’Leary from Shark Tank.
When asked why he put money into this industry, Mr. O’Leary, also known as “Mr.
Wonderful”, is recently quoted as saying:
“This could save lives, cure depression, help alcoholism, get people off
opioids—why wouldn’t I want to be invested?”
Wiser words may never have been spoken.
Other wealthy investors who are betting big on Psychedelic Medicine include:
Peter Thiel, who was a co-founder of PayPal and Facebook’s first outside
investor.
Steve Cohen, who is an American billionaire hedge fund manager. He has an
estimated net worth of $14.1 billion.
Thor Bjorgolfsson, who is Iceland’s first billionaire. His estimated net worth
is $2.2 billion.
Mike Novogratz, who is formerly a partner at Goldman Sachs. His net worth is
estimated at $600 million.
Billionaire entrepreneur Bob Parsons, founder of Go Daddy, with an estimated net
worth of over $2 billion dollars.
Money is coming in from hedge funds as well. The JLS Fund out of New York has
raised $50 million for its plant medicine fund... and is one of the more active
investment firms in the space. Simeon Schnapper, the firm’s founder is very
bullish on the sector.
He was recently quoted in Bloomberg as saying... “The possibilities for
psychedelics to be a new medicine and replace antidepressants is 100 times
greater than cannabis.”
The founders at Ei.Ventures concur... and believe the Future of Mental Health is
Psychedelic. The investment dollars flowing into the industry look like they’re
saying the same thing.


THE MARKETS HAVE SPOKEN

ATAI Life Sciences just became the third Psychedelic company to go public on the
Nasdaq. Their share jumped over 30% on the day of its IPO which was Friday, June
18th. This gave the company a valuation of nearly $3 billion dollars after its
first day of trading.
Compass Pathways, which went public back in September 2020 is currently sporting
a market cap of roughly $1.5 billion dollars.
There’s a huge appetite for winning on Wall Street... and many believe that the
psychedelic medicine industry could potentially be the next big healthcare
growth trend.
To this point... over $500 million was raised between September of 2020 and
January of 2021. $371 million of that total was raised by public companies.
Ei.Ventures believes the public markets are saying “Yes” to the industry...
right now.
It’s one of the reasons why the company is thrilled to announce their Reg A+
Tier 2 offering is now open to non-accredited investors and accredited investors
alike.
Keep in mind there are several market segments which Ei.Ventures is targeting
with their Botanical Psychedelic formulations... and they are all billion dollar
markets.
Here are some numbers to be aware of:
The global PTSD therapeutics market is projected to reach $10.7 billion by 2026
with a CAGR of 4.5% per year from 2018 to 2026.
The global depression drugs market is expected to reach $17.3 billion by the end
of 2024, growing at 2.9% per year between 2019 and 2024.
The global addiction treatment market, which includes nicotine, alcohol and
opioid addiction, is projected to reach $7 billion by 2026... with a CAGR of
6.7% from 2019 to 2027.
The global market for the treatment of generalized anxiety disorder is projected
to hit $7.5 billion by 2023.
One more thing... Psychedelic medicine and assisted therapies could potentially
help save vast sums of treatment dollars. For example, researchers suggest that
the savings from a potential MDMA-based therapy for PTSD could be a sizable
$103,000 per patient. Their peer-reviewed findings were published in the journal
PLOS One.
It’s important to note that none of this guarantees the industry will live up to
its potential and return handsome rewards for early stage investors. That
said... if these 4 data points continue to trend in a position direction... Ei.
Ventures believes it is on the right track to turn its psychedelic medicine
vision into reality.


THINKING TO INVEST IN THIS COMPANY?

Click The Button Below To Get Started
Invest Now


HOW EI.VENTURES INTENDS TO LEAD FROM THE FRONT

Ei.Ventures was born on the island of Maui in Hawaii. Two of the company's
co-Founders came to Hawaii over a decade ago to advance the cause of plant
medicines, beginning with both medical and recreational marijuana.
The CEO of the company, David Nikzad, has been a pioneer in the plant medicine
space since 1996, when he opened the first medical marijuana dispensary in
California.
For the last three years, David and the team at Ei.Ventures have been developing
their Psychedelic Solutions and their Flagship formulation, Psilly.
Their vision is inspired in part by the ancient history and traditions of the
Hawaiian islands.
There's a reason the islands are considered magical... it's the land itself.
It’s a place of ancient history as well.
Over there, the language is different as well. Words have special meanings,
which speak to bygone eras when the people lived in harmony with the land.
Two words, in particular, come to mind. The first is Aina... a Hawaiian word
which means, “the land which feeds us”. And it’s not just the physical side of
life... the land nourishes the whole person. This means the body, mind and
spirit.
The second word is Mana. This is the sacred energy Hawaiians believe all nature
is infused with... including the plants which grow in the earth. Mana is not
something which can be duplicated by human science in a lab.
Ei.Ventures was founded in part, on what these two words represent... to honor
this wisdom and energy of the land, along with the medicinal plants which grow
on it.
They believe the future of Psychedelic Medicine is Synergistic... not Synthetic.
To this end, they use the whole plant and fungi in their Psilocybin and other
botanical psychedelic formulations. What’s more, they also have a line of
medicinal mushroom products which are non-psychoactive and whole plant based.
As they see it, these plant medicines and vertical markets can and should be a
part of a holistic approach to mental health and wellness.
Better still, Ei.Ventures envisions them as the treatment option of choice and
the new standard of care. Their R&D efforts are geared towards this end.
This is how Ei.Ventures intends to lead from the front.


THE ROAD TO BETTER MENTAL HEALTH BEGINS WITH PSILLY

From the early days of the medical marijuana movement... to the present day
opportunity with psychedelic medicines... Ei.Ventures and its founders have been
at the forefront of these two major paradigm shifts.
Over the last 3+ years they have been quietly assembling their team... and
acquiring an extensive library of Botanical Psychedelic API. They have invested
several million dollars in R&D to date.
The company believes their that several of their unique formulations could
potentially become the de facto standard in the industry.
This is particularly true of their flagship product, Psilly. The formulation
starts with natural fungal extracts... which is their Botanical Psilocybin API
compound.
Next, the high-quality psilocybin extract is combined in a stacked
formulation... with other naturally occurring and complementary plant extracts.
Think Entourage Effect. The resulting synergy of compounds creates a unique
“psilocybin signature” ... which the company believes could potentially be the
best of breed.
They also believe that a minimal effective dose (MED) of Psilly will have
virtually zero hallucinogenic effect... while still providing patients with the
therapeutic benefits of Psilocybin.
The goal is to develop the Botanical Psychedelic API for the medical research
and therapeutic markets... and to potentially license this API into these same
markets.
What’s more, they are finalizing an agreement with a world-class research lab to
develop unique delivery mechanisms for Psilly as well.
This is part of their holistic strategy to provide solutions across multiple
levels of the mental health treatment spectrum.
Psilly could potentially be through pre-clinical and phase 1 trials within 18-24
months... and ready to launch into legal jurisdictions.
At the moment, the focus is on moving Psilly through the FDA new drug approval
process and securing the patents as well.
Ei.Ventures also holds the IP for the extraction process of two other botanical
API compounds, DMT and MDMA. Along with Psilly, there are the big three which
the company believes could help radically improve mental health... potentially
for millions.


THE FUTURE OF MENTAL WELLNESS: MANA AND TELEPSYCHIATRY

In addition to the development of their psychedelic medicines... for both
therapeutic use and to potentially license to the API to various markets... the
big picture includes the launch of their mental wellness platform as well.
This is another spoke to their revenue model which helps further set them apart
from other companies in the space. The platform is designed is to empower and
support people to go from mental illness to mental health... no matter where
they are starting on the journey.
It starts with their line of medicinal mushroom nutraceuticals they are
developing for the consumer market. These too are whole-plant based.
The first to be released is called Brain MANA... which is designed to help
improve and support brain health, mental clarity and overall well-being.
Brain MANA is made from an exclusive blend of organic and non-psychoactive
medicinal mushrooms. This includes 4 varieties of organic Cordyceps, organic
Turkey Tail as well as organic Shitake. These are non-psychoactive mushrooms.
Their other MANA formulations will target improving immune health, sexual
function, sleep quality, joint health and vitality.
As part of their Mental Wellness platform, the company is also planning to
launch a Telepsychiatry App. This app will be designed to support patients and
wellness-seekers on their healing journeys.
An agreement is in place with a leading developer... and the beta version of the
app may provide features like health-sensing data, mind-body practices and other
interactive virtual care options.
The app may also provide psychedelic resources for the mental health
community... and have the ability to link up therapists with their patients as
well.
The vision for this platform is to help usher in a new era of mental wellness
for those who need help right now... and for those already on their way to
better mental health.


THE COMING GOLDEN AGE OF PSYCHEDELIC MEDICINE IS NOW

Sometimes a single idea... if big enough and bold enough... can alter the course
of human history... and make a difference for millions.
Ei.Ventures believes Psychedelic Medicine is such an idea... and perhaps it was
meant to come along at this precise time in our lives.
There are close to a billion people struggling with mental illness... and that
was before Covid-19 put a stranglehold on the world.
Today, the global mental health crisis has gone from really bad to even worse.
Thankfully... Psychedelic plant medicines are being re-discovered just in time.
Results from numerous clinical trials continue to show the potential these
medicines have to transform the multi-billion dollar mental health treatment
market.
Canada-based investment banking firm Canaccord Genuity believes the market for
psychedelic medicines could potentially be a $100 billion market.
An emerging industry is changing the mental health paradigm. Early-stage
investors like Kevin O’Leary from Shark Tank are betting big on the industry...
and could potentially see a handsome return on their investments.
The idea itself that Psychedelic Medicine could potentially put an end to
anxiety, and other conditions like depression, PTSD and opioid addiction...
Well, this sure seems like something we could all root for.
A New Era Of Mental Health Freedom Awaits
If you’re looking for a chance to get in at the early stages of this growing
industry... we invite you to consider investing in Ei.Ventures.
Ei.Ventures is the first Psychedelic Medicine company in the world to qualify
for a Reg A+ Tier 2 offering. It’s an opportunity they’re excited about...
because it gives both non-accredited and accredited investors a chance to join
the movement.
It also gives more everyday folks a chance to invest in an early stage company
they might not otherwise ever know or hear about.
As Ei.Ventures sees it, this is a great time to be part of the psychedelic
industry... and there are several reasons why:
The mental health epidemic is real... with nearly 1 billion people worldwide
struggling with one or more forms of mental illness. The need of the hour is
great.
Existing mental health treatment options are not getting the job done. Studies
show that over 50% of patients stop taking their antidepressants. Rehab for
patients with harmful addictions can be a revolving door of failure.
Big Pharma has turned their attention away from Psychiatric drugs... opening the
door for potentially more safe and effective psychedelic solutions. Going back
to 2016, drug companies have reduced their spending on new drug development by
70%.
Clinical trials using psychedelic-based therapies are generating promising
treatment results... on a consistent basis. Those suffering from mental illness
have good reason to hope.
Money is coming into the sector at a fast clip... fueling a growth trend that
could possibly mirror how the medical marijuana industry took off.

Research is confirming what the ancient traditions have known for thousands of
years... there is a healing power to these plant medicines. With this in mind...
One of the big goals at Ei.Ventures is to develop and then deploy their novel
Psychedelic therapeutic solutions... as it becomes legal to do so... to those
who need it most.
And through their Reg A+ Tier 2 offering... you have an opportunity to invest in
what could potentially become the de facto standard for Botanical Psilocybin API
to the industry.
For those who struggle with mental illness every day... this is a future to
believe in.


INVEST NOW IN THE FUTURE OF MENTAL HEALTH

Click The Button Below To Get Started
Invest Now


FAQ


HOW CAN I PLACE MY INVESTMENT?




WHEN WILL THE FULLY EXECUTED SUBSCRIPTION AGREEMENT BE SENT?




WHO IS THE TRANSFER AGENT?




HOW LONG DOES PAYMENT PROCESS TIME TAKE?




WHAT PAYMENT OPTIONS ARE AVAILABLE?




DO YOU NEED TO BE AN ACCREDITED INVESTOR?




ARE THERE ARE ANY WARRANTS INVOLVED IN THIS OFFERING?




WHAT ACCOUNT TYPES CAN I INVEST WITH?




I’M HAVING TROUBLE INVESTING, MY PAYMENT WENT THROUGH, BUT WAS REJECTED ON YOUR
END. WHY IS THIS HAPPENING AND HOW COULD I SECURE MY INVESTMENT?




WHAT HAPPENS IF I GET LOCKED OUT OF MY DEALMAKER ACCOUNT?




WILL YOU SEND A STOCK CERTIFICATE OR OTHER 'PROOF' OF INVESTMENT?




HOW DO I CONTACT THE COMPANY FOR ASSISTANCE?




I MADE A TYPING MISTAKE WHEN SIGNING UP, HOW CAN I FIND A REMEDY FOR IT?


Enter Your Email to Get Started

Get Started
We value your privacy and information


2021 (c) Ei.Ventures, Inc. All rights reserved.
Privacy Policy
Legend: AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE
SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE
COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT
DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON
THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. THE
OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AT:
https://www.sec.gov/Archives/edgar/data/1823182/000110465921038430/a20-30556_1partiiandiii.html
YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.
Forward Looking Statements: Certain information set forth in this presentation,
together with any supplements and any other information that may be furnished to
prospective investors by the Company in connection therewith, contains
“forward-looking statements” and “forward-looking information” within the
meaning of applicable United States securities legislation (referred to herein
as forward-looking statements). Except for statements of historical fact,
certain information contained herein constitutes forward-looking statements
which include but are not limited to statements related to activities, events or
developments that Ei.Ventures expects or anticipates will or may occur in the
future, statements related to the Company’s business strategy objectives and
goals, and management’s assessment of future plans and operations which are
based on current internal expectations, estimates, projections ,assumptions and
beliefs, which may prove to be incorrect. Forward-looking statements can often
be identified by the use of words such as “may”, “will”, “could”, “would”,
“anticipate”, ‘believe”, expect”, “intend”, “potential”, “estimate”, “budget”,
“scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions or
the negatives thereof. Forward-looking statements are neither historical facts
nor assurances of future performance. Forward-looking statements are based on a
number of factors and assumptions made by management and considered reasonable
at the time such information is provided, and forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause the
actual results, performance or achievements to be materially different from
those expressed or implied by the forward-looking statements.
Sources and References
https://www.singlecare.com/blog/news/mental-health-statistics/
https://www.hopkinsmedicine.org/Press_releases/2006/07_11_06.html
https://www.psychiatrictimes.com/view/mental-illness-will-cost-world-16-usd-trillion-2030
https://www.psychalive.org/what-its-like-to-live-with-mental-disorder/
https://www.healthaffairs.org/doi/10.1377/hlthaff.2018.05246
https://www.constellationbehavioralhealth.com/blog/the-real-cost-of-untreated-mental-illness-in-america/
https://www.rxlist.com/prozac-side-effects-drug-center.htm
https://journals.lww.com/md-journal/fulltext/2020/12180/antidepressant_adherence_and_its_predictors_in.12.aspx
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518696/
https://www.webmd.com/mental-health/news/20181227/ptsd-drug-may-do-more-harm-than-good
https://journals.sagepub.com/doi/full/10.1177/2470547020939564
https://psychedelicreview.com/the-entourage-effect-in-magic-mushrooms/
https://www.marketresearchfuture.com/reports/medicinal-mushroom-extract-market-4737
https://www.grandviewresearch.com/industry-analysis/telepsychiatry-market
https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/chem.201904363
https://psilocybinalpha.com/news/the-psychedelic-renaissance-in-2020
https://www.tandfonline.com/doi/full/10.1080/02791072.2019.1580804
https://www.sciencedaily.com/releases/2021/07/210705113923.htm
https://www.self.com/story/psychedelic-therapy
https://psilocybinalpha.com/data/psilocybin-patent-filings-tracker
https://psilocybinalpha.com/news/the-psychedelic-renaissance-in-2020
https://psilocybinalpha.com/data/psychedelic-drug-development-tracker
https://health.ucsd.edu/news/releases/Pages/2021-02-17-new-grant-funds-clinical-trial-to-assess-psychedelic-as-treatment-for-phantom-limb-pain.aspx
https://www.fastcompany.com/90436824/silicon-valleys-psychedelic-wonder-drug-is-almost-here
https://investingwhisperer.com/investing-in-psychedelics/
https://www.bloomberg.com/news/articles/2020-12-11/psychedelics-replace-pot-as-the-new-favorite-edgy-investment
https://psychedelicstockwatch.com/psychedelic-stock-news/follow-the-money-us-500-million-in-new-psychedelics-financing-powering-massive-growth
https://maps.org/news/media/8363-press-release-study-mdma-assisted-psychotherapy-will-be-cost-effective-in-the-treatment-of-ptsd
https://www.baystreet.ca/stockstowatch/9311/Psychedelic-Drugs-Could-Create-a-100-Billion-Investment-Opportunity
https://www.theguardian.com/society/2016/jan/27/prozac-next-psychiatric-wonder-drug-research-medicine-mental-illness